- Nepicastat
-
- $3520.00
-
2026-04-20
- CAS:173997-05-2
- Purity:
- Supply Ability: 10g
- Nepicastat
-
-
2025-04-04
- CAS:173997-05-2
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 1Ton
- Nepicastat
-
- $15.00
-
2021-07-13
- CAS:173997-05-2
- Min. Order: 1KG
- Purity: 99%+ HPLC
|
| | Nepicastat Basic information |
| Product Name: | Nepicastat | | Synonyms: | Nepicastat;Nepicastat [inn];5-(AMinoMethyl)-1-((S)-5,7-difluoro-1,2,3,4-tetrahydro-2-naphthyl)-4-iMidazoline-2-thione;5-(Aminomethyl)-1-[(2S)-5,7-difluoro-1,2,3,4-tetrahydro-2-naphthalenyl]-1,3-dihydro-2H-imidazole-2-thione;RS-25560-197;SYN117;Nepicastat (free base) (SYN-117);Nepicastat HCl | | CAS: | 173997-05-2 | | MF: | C14H15F2N3S | | MW: | 295.35 | | EINECS: | | | Product Categories: | API | | Mol File: | 173997-05-2.mol |  |
| | Nepicastat Chemical Properties |
| Boiling point | 401.8±55.0 °C(Predicted) | | density | 1.40 | | storage temp. | Store at -20°C | | solubility | DMSO: ≥ 48 mg/mL (162.52 mM) | | form | Powder | | pka | 11.69±0.70(Predicted) |
| | Nepicastat Usage And Synthesis |
| Uses | Treatment of congestive heart failure (dopamine β-hydroxylase inhibitor). | | Definition | ChEBI: Nepicastat is a member of the class of 1,3-dihydroimidazole-2-thiones that is 1,3-dihydro-2H-imidazole-2-thione in which one of the nitrogens is substituted by a 5,7-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl group while the carbon adjacent to it is substituted by an aminomethyl group (the S enantiomer). It is a potent and selective inhibitor of both bovine and human dopamine beta-hydroxylase, an enzyme that catalyzes the conversion of dopamine to norepinephrine. It has a role as an EC 1.14.17.1 (dopamine beta-monooxygenase) inhibitor. It is a member of tetralins, an organofluorine compound, a primary amino compound and a member of 1,3-dihydroimidazole-2-thiones. | | in vivo | Nepicastat (3-100 mg/kg; p.o.; three consecutive times, 12 hours apart times) produces dose-dependent decreases in noradrenaline content, increases in dopamine content and increases in dopamine/noradrenaline ratio in the artery (mesenteric or renal), left ventricle[3]. | Animal Model: | 15-16 weeks male spontaneously hypertensive rats (SHRs)[3] | | Dosage: | Oral administration; three consecutive times, 12 hours apart | | Administration: | 3, 10, 30, 100 mg/kg | | Result: | Produced dose-dependent decreases in noradrenaline content, increases in dopamine content and increases in dopamine/noradrenaline ratio in the artery (mesenteric or renal), left ventricle and cerebral cortex. |
| | target | DBH |
| | Nepicastat Preparation Products And Raw materials |
|